A recent phase II trial demonstrated that the combination of docetaxel-based chemotherapy and dexamethasone showed significantly high prostate-specific antigen (PSA) responses compared with previous studies in patients with castration-resistant prostate cancer (CRPC).1
However, the response seen in this trial was excellent, and hopefully more research building on these results will likely be the subject of future trials.
One prior study investigating the efficacy and toxicity of low-dose docetaxel combined with dexamethasone found that 65% of evaluable patients had a decrease in their PSA responses >50%.2
The study concluded that low-dose docetaxel in combination with dexamethasone is feasible in patients with CRPC. Grade 3 febrile neutropenia occurred in 2 patients (5%). Nonhematological toxicities were less frequent but sometimes severe. Treatment-related death occurred in 2 elderly patients, due to gastric bleeding in one and to infective endocarditis in the other. Hematological toxicity was less than that seen with standard docetaxel therapy, but it was necessary to monitor patients during the study for severe nonhematological toxicities, particularly in elderly patients.2
... to read the full story